Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
Recruitment status was: Active, not recruiting
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma|
|Study Start Date:||July 1999|
- Determine complete, partial, or stable response to hydroxyurea in patients with recurrent and/or nonresectable meningioma.
- Determine response at 2 years to this regimen in these patients.
- Determine overall and disease free survival of these patients after this regimen.
- Determine quality of life of these patients.
- Determine the toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to grade of disease (I vs II or III).
Patients receive oral hydroxyurea daily for 2 years.
Quality of life is assessed before treatment, then every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006119
|Hopital Saint Andre|
|Bordeaux, France, 33075|
|Centre Leon Berard|
|Lyon, France, 69373|
|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle|
|Montpellier, France, 34298|
|Centre Eugene Marquis|
|Rennes, France, 35042|
|Centre Hospitalier Universitaire Bretonneau de Tours|
|Tours, France, 37044|
|Study Chair:||Didier Frappaz, MD||Centre Leon Berard|